Abstract
HIF-1α (hypoxia-inducible factor 1 alpha) is believed to promote oesophageal squamous tumour growth. Thus, an HIF-1α inhibitor is viewed as a therapeutic target in treating oesophageal cancer. Recently, YC-1 [3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole] has been widely used as a potential HIF-1α inhibitor and is being developed as a novel anticancer drug. However, little is known about the effects of YC-1 in human oesophageal cancer. In the present study, we aimed to investigate these effects in an esophageal squamous cancer cell line; i.e. Eca109 cells. We found that YC-1 abolished the hypoxia-induced up-regulation of HIF-1α. YC-1 arrested cell growth and inhibited cell migration activities in Eca109 cells. These results suggest that YC-1 may be a chemotherapy candidate against oesophageal squamous cancers.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Carcinoma, Squamous Cell / drug therapy*
-
Carcinoma, Squamous Cell / genetics
-
Carcinoma, Squamous Cell / metabolism
-
Cell Cycle / drug effects
-
Cell Line, Tumor
-
Cell Movement / drug effects
-
Cell Proliferation / drug effects
-
Esophageal Neoplasms / drug therapy*
-
Esophageal Neoplasms / genetics
-
Esophageal Neoplasms / metabolism
-
Gene Expression Regulation, Neoplastic / drug effects
-
Humans
-
Hypoxia-Inducible Factor 1, alpha Subunit / antagonists & inhibitors*
-
Hypoxia-Inducible Factor 1, alpha Subunit / genetics*
-
Hypoxia-Inducible Factor 1, alpha Subunit / metabolism
-
Indazoles / pharmacology*
-
Up-Regulation / drug effects
Substances
-
Antineoplastic Agents
-
Hypoxia-Inducible Factor 1, alpha Subunit
-
Indazoles
-
3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole